SCHEDULE: FMR LLC Reports 8.8% Stake in Immunocore Holdings PLC
Beneficial Ownership Filing (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Immunocore Holdings PLC's common stock as of June 30, 2026.
Summary
- FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating their beneficial ownership of Immunocore Holdings PLC's common stock.
- As of June 30, 2026, the aggregate amount beneficially owned is 4,307,246 shares, representing 8.8% of the class.
- FMR LLC, organized in Delaware, holds sole voting power for 4,302,916 shares and sole dispositive power for 4,307,246 shares.
- Abigail P. Johnson, a U.S. citizen, has sole dispositive power over 4,307,246 shares.
- FIAM LLC and Fidelity Management Trust Company are identified as subsidiaries of FMR LLC involved in the beneficial ownership.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a performance or strategic announcement.
Positives
- Significant institutional ownership by FMR LLC, suggesting confidence in the company's long-term prospects.
- Clear disclosure of beneficial ownership, promoting transparency for investors.
Negatives
- The filing does not contain financial performance data or strategic updates, limiting insight into the company's operational health.
Risks
- The filing does not explicitly mention any risks.
- Potential for future changes in beneficial ownership by FMR LLC could impact share price.
Future Outlook
This filing is an update on beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.
Management Comments
- FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors increasing or maintaining significant stakes in publicly traded companies. This filing indicates FMR LLC's continued interest in Immunocore Holdings PLC.
Comparison to Industry Standards
- The 8.8% ownership stake by FMR LLC is a substantial holding for an institutional investor in the biotechnology sector, often indicating a belief in the company's development pipeline or market position.
Stakeholder Impact
- Shareholders: Increased institutional ownership can be seen as a positive signal, potentially leading to greater stability or influence on corporate strategy.
- Management: The significant stake held by FMR LLC may influence discussions regarding corporate strategy and governance.
Next Steps
- Continued monitoring of FMR LLC's ownership stake in Immunocore Holdings PLC.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/10/2023 | FMR LLC Schedule 13G filing referenced in power of attorney. |
| 01/31/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 01/31/2023 | FMR LLC Schedule 13G filing referenced in power of attorney. |
| 06/30/2026 | Date of event requiring filing of this statement (ownership as of this date). |
| 08/05/2026 | Date of joint filing of Schedule 13G and Rule 13d-1(k)(1) agreement. |
Keywords
Immunocore Holdings PLC, Schedule 13G, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.